Efficacy of tiotropium bromide on spirometric measurements and control of asthma in real life: data from a 1-year clinical follow-up
Journal of Asthma, cilt.62, sa.9, ss.1584-1590, 2025 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 62 Sayı: 9
- Basım Tarihi: 2025
- Doi Numarası: 10.1080/02770903.2025.2499823
- Dergi Adı: Journal of Asthma
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE, Psycinfo
- Sayfa Sayıları: ss.1584-1590
- Anahtar Kelimeler: Asthma, asthma control test, forced expiratory volume in one second (FEV1), forced vital capacity (FVC), respiratory volumes, tiotropium
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Objective: Real-life studies are needed to evaluate the clinical outcomes of add-on tiotropium therapy in patients with asthma. The effects of adding tiotropium bromide to the treatment of asthmatic patients on pulmonary functions and asthma control using real-life data. Methods: In a retrospective study, spirometric measures and asthma control states were compared before and one year after of tiotropium treatment in asthmatic adults whose disease was not adequately controlled with a combination of inhaled corticosteroids and long-acting β2-agonists. Results: One year after tiotropium treatment, mean FEV1, FEV1%, and FEV1/FVC ratio increased significantly compared to pretreatment values. Among 32 patients added tiotropium due to symptomatic asthma, 28 (87.5%) patients achieved well-controlled (ACT ≥ 20) end of the year and GINA treatment step-down in 4 (12.5%) patients. Monoclonal antibody therapies (mepolizumab or omalizumab) were initiated in 9 patients (28.1%). FEV1 values and FEV1/FVC ratios showed a statistically significant improvement from baseline measurements obtained prior to the initiation of tiotropium therapy, independent of monoclonal antibody use (p <.001 for each). The mean age of these patients was 48.78 ± 11.64 (range: 28–81) years, and 25 (78.1%) of them were female. Conclusions: Tiotropium bromide is an effective and reliable add-on therapy for symptomatic asthma when combined with ICS plus LABA, also leads to improvements in respiratory function and asthma control.